28,019 press releases indexed under finance.
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 46,354 IPC common shares (ISIN: CA46016U1084) during the period of September 7 to 11, 2026 under IPC’s previously announced normal course issuer bid / share repurchase program (NCIB).
Board Authorization Reflects Confidence in Solidion's Long-Term Strategy and Commitment to Enhancing Shareholder Value DALLAS, Sept. 14, 2026 /PRNewswire/ -- Solidion Technology, Inc. (NASDAQ: STI) ("Solidion Technology" or "the Company"), an advanced battery technology solutions...
Til Nasdaq Copenhagen A/S 14. september 2026 Meddelelse nr. 76/2026 Intern viden
To Nasdaq Copenhagen A/S 14 September 2026 Announcement no. 76/2026 Inside information
NEW YORK, Sept 14, 2026 - (ACN Newswire) - Londian Wason New Energy Tech Inc. (NYSE: FOIL), a global innovation-driven developer and manufacturer of electrolytic copper foil, recently announced the closing of the sale of an additional 626,104 American Depositary Shares (ADSs) pursuant to the partial exercise of the underwriters' over-allotment option granted in connection with its initial public offering (IPO). The option was exercised at the IPO price of USD22.00 per ADS. Including the previously announced IPO gross proceeds of USD94,285,708, the company raised aggregate gross proceeds of USD108,059,996 prior to deducting underwriting discounts, commissions, and offering expenses. Cantor Fitzgerald & Co., Huatai Securities (USA), Inc., CMB International Capital Limited, and US Tiger Securities acted as representatives of the underwriters for the offering. Londian Wason is an integrated materials enterprise specializing in R&D, manufacturing, and sales of high-performance new energy and electronic materials. It is China’s first manufacturer to develop 6μm high-strength LiB copper foil and the world’s first one to be capable of mass producing 6μm LiB copper foil. The company also has large-scale mass production capacity for 4μm high-tensile and high-strength LiB copper foil. The Company’s broad product suite ranges from ultra-thin battery foils to PCB-grade foils covering HTE to HVLP specifications, serving diverse end markets including electric vehicles (EVs), energy storage systems (ESS), telecommunications, and consumer electronics. Its PCB copper foil delivers high signal integrity and minimal signal attenuation for high-frequency, high-speed transmission, supporting next-generation advanced computing clusters. In the PCB copper foil segment, Londian Wason has served as a key supplier to Panasonic Industrial Materials for 12 consecutive years. As AI-driven demand for computing infrastructure surges exponentially, high-frequency and high-speed PCB copper foil has become a critical material for AI servers and high-speed switches. According to Frost & Sullivan, Londian Wason shipped approximately 111,985 metric tons of lithium battery copper foil in 2025, ranking No.1 globally by annual sales volume. The primary purposes of this offering are for global production expansion and upgrade, including building new manufacturing facilities, purchasing advanced production equipment, and expanding capacity via potential strategic investments and acquisitions, and for the R&D of advanced technologies, high-efficiency manufacturing processes, expanded product portfolios and application scenarios, as well as for general corporate purposes, such as capital requirements and attracting and retaining industry talent. The offering was conducted under the company’s Registration Statement on Form F-1, declared effective by the U.S. Securities and Exchange Commission on August 11, 2026. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com
Monday 14 September, 2026 Hereford, UK 14 September 2026: Synalogik Innovative Solutions Ltd (“Synalogik”), the developer of an Intelligence Operating Platform for investigators, compliance and risk professionals, has completed an extension to its Series A funding round, taking total investment in the company to £12.5 million. The latest funding round was supported by a group of existing and new shareholders. Shareholders include the Mark Blandford family offices; William Currie Group; and Sir Terry Leahy. Founded in 2018, Synalogik was built around a simple premise: the people who understand the problem should have the power to solve it. Over the last 18 months it has transitioned from being Professional Services led to a SaaS focused business, leveraging its cutting edge AI enabled platf
- - • Funding Commitment: Signing of binding agreement provides for up to USD1 billion in combined equity commitments from Space42 and Viasat as the initial co-founders of Equatys - • Program Progression: Simultaneous signing of agreement to step-up funding accelerates program development of the initial satellite constellation; Scalable constellation's initial tranche to be awarded upon formation of Equatys with planned appointment of Viasat as prime technology contractor - • S... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=360431
MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial ( NCT05671510 ) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease progressed on prior immunotherapy and chemotherapy. Gotistobart is an investigational CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells (“Tregs”) within the tumor microenvironment and restore anti-tumor immune activity.
MAINZ, Deutschland, und ROCKVILLE, USA, 14. September 2026 – BioNTech SE (Nasdaq: BNTX, „BioNTech“) und OncoC4, Inc. („OncoC4“) gaben heute die ersten Daten zum medianen Gesamtüberleben (overall survival, „OS“) aus dem nicht-zulassungsrelevanten ersten Teil (stage 1) der globalen, randomisierten, klinischen Phase-3-Studie PRESERVE-003 ( NCT05671510 ) mit Gotistobart (auch bekannt als BNT316 oder ONC-392) bekannt. Die Studie untersucht Gotistobart bei Patientinnen und Patienten mit einem Plattenepithelkarzinom der Lunge (squamous non-small cell lung cancer, „squamous NSCLC“), deren Erkrankung nach einer vorangegangenen Immuntherapie und Chemotherapie fortgeschritten war. Gotistobart ist ein gegen den Immun-Checkpoint CTLA-4 gerichteter Immuntherapie-Kandidat, der regulatorische T-Zellen („T
NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.
NEW YORK, 14 sept. 2026 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS – NASDAQ: CLLS), société pionnière dans l'édition du génome, annonce que son conseil d’administration a approuvé le 11 septembre 2026 une transformation stratégique visant à devenir une société d’édition du génome in vivo , se consacrant au développement de traitements aux effets durables dans les maladies chroniques.
Patrick Delany appointed Chief Operating Officer to accelerate subscriber and revenue growth and drive tight integration across DAZN's divisions. Alex Gersh joins DAZN as Chief Financial Officer to lead financial strategy, capital allocation and group performance through DAZN's next phase....